Login to Your Account

Company to End Study Early

Ampio Gains on Positive Interim Phase II Data of Optina in DME

By Marie Powers
Staff Writer

Tuesday, March 20, 2012
Shares of Ampio Pharmaceuticals Inc. soared Monday after the biopharmaceutical company reported positive data from its interim review of the first 50 percent of patients enrolled in a Phase II study of Optina in diabetic macular edema (DME).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription